ImmunityBio Amends Revenue Interest Deal for $75M

ImmunityBio, Inc. entered into a Second Amendment to its Revenue Interest Purchase Agreement dated March 30, 2026. The amendment provides for a Third Payment in an aggregate principal amount of $75,000,000, subject to the terms of the existing purchase agreement.

The amendment is entered into among ImmunityBio, subsidiary guarantors, the required purchasers, and Infinity SA LLC as collateral agent and administrative agent for the purchasers. The effectiveness of the amendment depends on delivery of executed amendment documents and an irrevocable payment notice for the Third Payment.